| ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (NCT07011706) | Aclaris Therapeutics, Inc. | 2025-05-30 |
| Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT06585202) | Aclaris Therapeutics, Inc. | 2024-08-19 |
| Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis (NCT05511519) | Aclaris Therapeutics, Inc. | 2022-07-12 |
| Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis (NCT05432596) | Aclaris Therapeutics, Inc. | 2022-05-11 |
| ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA) (NCT05279417) | Aclaris Therapeutics, Inc. | 2022-02-01 |
| ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NCT05216224) | Aclaris Therapeutics, Inc. | 2021-12-29 |
| Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS) (NCT04524858) | Aclaris Therapeutics, Inc. | 2020-10-23 |
| Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis (NCT04598269) | Aclaris Therapeutics, Inc. | 2020-09-30 |
| Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA (NCT04247815) | Aclaris Therapeutics, Inc. | 2020-03-16 |
| Safety Study of A-101 Topical Solution for the Treatment of Common Warts (NCT03812510) | Aclaris Therapeutics, Inc. | 2019-02-07 |
| ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT) (NCT03759340) | Aclaris Therapeutics, Inc. | 2019-01-15 |
| Study of A-101 Topical Solution for the Treatment of Common Warts (NCT03687372) | Aclaris Therapeutics, Inc. | 2018-09-17 |
| A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis (NCT03585296) | Aclaris Therapeutics, Inc. | 2018-07-10 |
| ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis (NCT03594227) | Aclaris Therapeutics, Inc. | 2018-06-11 |
| Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata (NCT03551821) | Aclaris Therapeutics, Inc. | 2018-04-11 |
| A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution (NCT03495817) | Aclaris Therapeutics, Inc. | 2018-03-22 |
| An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (NCT03487588) | Aclaris Therapeutics, Inc. | 2018-03-21 |
| A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo (NCT03468855) | Aclaris Therapeutics, Inc. | 2018-03-19 |
| Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT) (NCT03315689) | Aclaris Therapeutics, Inc. | 2017-12-14 |
| Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea (NCT03380390) | Aclaris Therapeutics, Inc. | 2017-12-04 |
| A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata (NCT03354637) | Aclaris Therapeutics, Inc. | 2017-11-29 |